RxDoctor Payments DataLook up a doctor →

Andrea Espinoza, MD

Pulmonary Disease · Houma, LANPI 1700839495

Payments from drug & device makers

$654,731in general payments, 2019–2025

Across 710 payments — averaging $922.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$389K
  • Regeneron Healthcare Solutions, Inc.$140K
  • Sanofi$122K
  • Boehringer Ingelheim$897
  • GSK$699
  • Grifols USA, LLC$381
  • plus $1K from 15 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$654,731 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$13,139
Medicare patients
46
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →